Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line

N. Masumoto, S. Nakano, T. Esaki, T. Tatsumoto, H. Fujishima, Eishi Baba, M. Nakamura, Y. Niho

研究成果: ジャーナルへの寄稿記事

35 引用 (Scopus)

抄録

Background: We studied the modulatory effects of 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, on the antitumor activities of clinically important anticancer drugs including cisplatin (CDDP), 5-fluorouracil (5-FU), mitomycin C (MMC), etoposide (VP-16), and adriamycin (ADR). Materials and Methods: The HST-1 human carcinoma cells were treated with graded concentrations of these anticancer drugs either alone or in combination with IC50 concentration of SN-38, administered in several different treatment schedules, and antitumor activity was evaluated by the growth inhibition assay. Results: SN-38 potentiated the antitumor activity of CDDP in all schedules with a maximal effect observed with a simultaneous administration, while SN-38 enhanced the cytotoxicity of MMC, 5-FU, or VP-16 only in certain schedules. By contrast, SN-38 attenuated the anticancer effect of ADR in all schedules. Conclusions: These results demonstrate that SN-38 may have the advantage of augmenting the anticancer activity in combination with CDDP, MMC, 5-FU, and VP-16, depending on the schedule of administration, and should thus be incorporated into the design of a clinical trial for obtaining maximal therapeutic synergy.

元の言語英語
ページ(範囲)405-409
ページ数5
ジャーナルAnticancer Research
15
発行部数2
出版物ステータス出版済み - 1 1 1995

Fingerprint

irinotecan
Squamous Cell Carcinoma
Etoposide
Appointments and Schedules
Cell Line
Mitomycin
Fluorouracil
Pharmaceutical Preparations
Doxorubicin
Camptothecin
Cisplatin
Inhibitory Concentration 50

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. / Masumoto, N.; Nakano, S.; Esaki, T.; Tatsumoto, T.; Fujishima, H.; Baba, Eishi; Nakamura, M.; Niho, Y.

:: Anticancer Research, 巻 15, 番号 2, 01.01.1995, p. 405-409.

研究成果: ジャーナルへの寄稿記事

Masumoto, N, Nakano, S, Esaki, T, Tatsumoto, T, Fujishima, H, Baba, E, Nakamura, M & Niho, Y 1995, 'Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line', Anticancer Research, 巻. 15, 番号 2, pp. 405-409.
Masumoto, N. ; Nakano, S. ; Esaki, T. ; Tatsumoto, T. ; Fujishima, H. ; Baba, Eishi ; Nakamura, M. ; Niho, Y. / Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. :: Anticancer Research. 1995 ; 巻 15, 番号 2. pp. 405-409.
@article{8ea3c9ef2e2c4eb789c7fd549fa49a66,
title = "Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line",
abstract = "Background: We studied the modulatory effects of 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, on the antitumor activities of clinically important anticancer drugs including cisplatin (CDDP), 5-fluorouracil (5-FU), mitomycin C (MMC), etoposide (VP-16), and adriamycin (ADR). Materials and Methods: The HST-1 human carcinoma cells were treated with graded concentrations of these anticancer drugs either alone or in combination with IC50 concentration of SN-38, administered in several different treatment schedules, and antitumor activity was evaluated by the growth inhibition assay. Results: SN-38 potentiated the antitumor activity of CDDP in all schedules with a maximal effect observed with a simultaneous administration, while SN-38 enhanced the cytotoxicity of MMC, 5-FU, or VP-16 only in certain schedules. By contrast, SN-38 attenuated the anticancer effect of ADR in all schedules. Conclusions: These results demonstrate that SN-38 may have the advantage of augmenting the anticancer activity in combination with CDDP, MMC, 5-FU, and VP-16, depending on the schedule of administration, and should thus be incorporated into the design of a clinical trial for obtaining maximal therapeutic synergy.",
author = "N. Masumoto and S. Nakano and T. Esaki and T. Tatsumoto and H. Fujishima and Eishi Baba and M. Nakamura and Y. Niho",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "15",
pages = "405--409",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Sequence dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line

AU - Masumoto, N.

AU - Nakano, S.

AU - Esaki, T.

AU - Tatsumoto, T.

AU - Fujishima, H.

AU - Baba, Eishi

AU - Nakamura, M.

AU - Niho, Y.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background: We studied the modulatory effects of 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, on the antitumor activities of clinically important anticancer drugs including cisplatin (CDDP), 5-fluorouracil (5-FU), mitomycin C (MMC), etoposide (VP-16), and adriamycin (ADR). Materials and Methods: The HST-1 human carcinoma cells were treated with graded concentrations of these anticancer drugs either alone or in combination with IC50 concentration of SN-38, administered in several different treatment schedules, and antitumor activity was evaluated by the growth inhibition assay. Results: SN-38 potentiated the antitumor activity of CDDP in all schedules with a maximal effect observed with a simultaneous administration, while SN-38 enhanced the cytotoxicity of MMC, 5-FU, or VP-16 only in certain schedules. By contrast, SN-38 attenuated the anticancer effect of ADR in all schedules. Conclusions: These results demonstrate that SN-38 may have the advantage of augmenting the anticancer activity in combination with CDDP, MMC, 5-FU, and VP-16, depending on the schedule of administration, and should thus be incorporated into the design of a clinical trial for obtaining maximal therapeutic synergy.

AB - Background: We studied the modulatory effects of 7-ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, on the antitumor activities of clinically important anticancer drugs including cisplatin (CDDP), 5-fluorouracil (5-FU), mitomycin C (MMC), etoposide (VP-16), and adriamycin (ADR). Materials and Methods: The HST-1 human carcinoma cells were treated with graded concentrations of these anticancer drugs either alone or in combination with IC50 concentration of SN-38, administered in several different treatment schedules, and antitumor activity was evaluated by the growth inhibition assay. Results: SN-38 potentiated the antitumor activity of CDDP in all schedules with a maximal effect observed with a simultaneous administration, while SN-38 enhanced the cytotoxicity of MMC, 5-FU, or VP-16 only in certain schedules. By contrast, SN-38 attenuated the anticancer effect of ADR in all schedules. Conclusions: These results demonstrate that SN-38 may have the advantage of augmenting the anticancer activity in combination with CDDP, MMC, 5-FU, and VP-16, depending on the schedule of administration, and should thus be incorporated into the design of a clinical trial for obtaining maximal therapeutic synergy.

UR - http://www.scopus.com/inward/record.url?scp=0029016959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029016959&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 405

EP - 409

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -